CD274 and non-small cell lung carcinoma: Subsequent trials of neoadjuvant monotherapy PD-(L)1 inhibitors in resectable NSCLC patients were not as encouraging and found to have lower MPR rates of approximately 20%, similar to that seen with chemotherapy (Table 2) [20,21,22,23,24,25].